and Fcfusionproteinsfortherapeutic use MONOCLONAL ANTIBODIES Chronic lymphocyticleukaemia Systemic lupuserythematosus Acute lymphocyticleukaemia Non-Hodgkin’s lymphomas Acute myeloid leukaemia Head andneckcancer Merkel cellcarcinoma Paroxysmal nocturnal Fallopian tubecancer Castleman’s disease Hodgkin’s lymphoma Soft tissuesarcoma HAEMATOLOGIC DISEASES Colorectal cancer Malignant ascites Multiple myeloma Bone metastasis haemoglobinuria Cervical cancer Ovarian cancer Neuroblastoma Bladder cancer Gastric cancer Kidney cancer Breast cancer Lung cancer SOLID TUMORS IMMUNOLOGY Melanoma DISTRIBUTION OF INTERNATIONAL NONPROPRIETARY NAMES BY INDICATION avelumab olaratumab denosumab catumaxomab dinutuximab pembrolizumab nivolumab ipilimumab nivolumab bevacizumab bevacizumab bevacizumab bevacizumab cetuximab ramucirumab trastuzumab trastuzumab entansine pertuzumab bevacizumab trastuzumab atezolizumab aflibercept panitumumab cetuximab bevacizumab atezolizumab necitumumab nivolumab bevacizumab eculizumab elotuzumab daratumumab gemtuzumab ozogamicine inotuzumab ozogamicine blinatumomab obinutuzumab ofatumumab alemtuzumab rituximab obinutuzumab inotuzumab ozogamicine brentuximab vedotin ibritumomab tiuxetan rituximab nivolumab brentuximab vedotin siltuximab belimumab Chronic spontaneous urticaria Ankylosing spondylitis Rheumatoid arthritis Multiple sclerosis GASTROENTEROLOGY Psoriatic arthritis Ulcerative colitis Crohn’s disease Juvenile arthritis Gouty arthritis Osteoporosis RHUMATOLOGY DERMATOLOGY NEUROLOGY Psoriasis omalizumab ixekizumab secukinumab ustekinumab adalimumab infliximab etanercept ustekinumab vedolizumab adalimumab infliximab vedolizumab golimumab adalimumab infliximab denosumab canakinumab canakinumab tocilizumab abatacept adalimumab etanercept secukinumab certolizumab pegol golimumab adalimumab etanercept infliximab secukinumab certolizumab pegol ustekinumab golimumab infliximab adalimumab etanercept golimumab certolizumab pegol tocilizumab abatacept rituximab adalimumab infliximab etanercept daclizumab alemtuzumab natalizumab
Familial hypercholesterolemias Clostridium difficileinfections Idiopathic thrombocytopenic Severe eosinophilicasthma ENDOCRINOLOGY AND METABOLISM Graft versus hostdisease HAEMOSTASIS AND THROMBOSIS Prevention ofrespiratory Percutaneous coronary syncytial virus infection Reversal ofdabigatran Age relatedmacular Transplant rejection neovascularization Atypical hemolytic Cryopyrinopathies uremic syndrome INFECTIOUS DISEASES Anthrax infection Myopic choroidal Unstable angina Type 2diabetes Allergic asthma Macular edema TRANSPLANTATION GENETIC DISEASES Haemophilia A Haemophilia B OPHTALMOLOGY degeneration Prevention of intervention PNEUMOLOGY purpura romiplostim abciximab idarucizumab eftrenonacog α efmoroctocog α eculizumab canakinumab alirocumab evolocumab omalizumab reslizumab mepolizumab dulaglutide inolimomab belatacept basiliximab ranibizumab aflibercept ranibizumab aflibercept ranibizumab bevacizumab aflibercept obiltoxaximab raxibacumab palivizumab bezlotoxumab
03/2017 Université François-Rabelais - SID’com - Alexandra Louault